Halozyme Therapeutics HALO Change in Inventories
Change in Inventories at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInInventories.
The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Halozyme Therapeutics's change in inventories.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Halozyme Therapeutics's change in inventories?
- Halozyme Therapeutics (HALO) reported change in inventories of -$27.38M in Q1 2026.
- How has Halozyme Therapeutics's change in inventories changed year-over-year?
- Halozyme Therapeutics's change in inventories decreased by 4772.2% year-over-year, from $586K to -$27.38M.
- What is the long-term trend for Halozyme Therapeutics's change in inventories?
- Over 3 years (2021 to 2025), Halozyme Therapeutics's change in inventories has grown at a -30.0% compound annual growth rate (CAGR), from -$7.46M to -$2.55M.
- What does change in inventories mean?
- The change in the value of goods held in stock for sale or production.
- How do you interpret change in inventories?
- An increase in inventory consumes cash and may signal slowing sales or overproduction.
- How does change in inventories compare across companies?
- Standard metric for manufacturing and retail; peers are compared based on inventory turnover ratios.